NTT
15.5.2020 08:02:11 CEST | Business Wire | Press release
NTT Corporation (NTT, President & CEO: Jun Sawada) concluded a Cooperation Agreement on the ITER Project with the ITER International Fusion Energy Organization (ITER Organization).
By supporting the ITER Project, which has the objective of building the world’s first experimental hydrogen fusion reactor, NTT will accelerate “Development of innovative environment and energy technologies”, and contribute to the reduction of the environmental impact of customers, companies and society.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005951/en/
1. Background
The ITER Project is an extraordinarily large international project that has the objective of building the world’s first experimental hydrogen fusion reactor (ITER) to prove the scientific and technical feasibility of the fusion energy for peaceful purposes. The ITER Organization, an international organization with seven members – Japan, the European Union, Russia, the United States, South Korea, China, and India – is engaged in the ITER Project.
NTT is aiming at “Zero Environmental Impact” by supporting customers, enterprises, and society in reducing their impact on the environment through our R&D aimed at creating innovations that break through conventional limitations and by pursuing business activities designed to decrease deleterious effects on the environment. For example, NTT is preparing to establish the Space Environment and Energy Laboratories, which will undertake research with the goal of creating innovative energy and environmental technologies.
NTT assumes the use of photonic technologies developed for IOWN* concept, and will work to extend the current ICT technologies, which would benefit the ITER Project.
*IOWN (Innovative Optical and Wireless Network) is a future communications infrastructure to create a smarter world by using cutting-edge technologies like photonics and computing technologies.
https://www.rd.ntt/e/iown/
2. Scope of Cooperation
Under the strategic intent of this Cooperation Agreement, NTT will collaborate in the following areas.
- Exploration of innovative future Information and Communication Technology, including ultra-high-speed network, ultra-low latency network connectivity, data storage, computing, and global network infrastructure.
- Exploration of the concept “IOWN” including All-Photonics Network, Digital Twin Computing, and Cognitive Foundation.
This is the first time that the ITER Organization has signed a Long Term Non-Commercial Cooperation Agreement with a private Japanese company. As a general ICT player capable of providing full-stack, full-lifecycle services on a global scale, the NTT Group will collaborate on information distribution and control platforms in preparation for ITER’s first plasma in 2025 and beyond.
NTT will work out the details and conclude an implementation agreement.
3. Executive statements
“With an aim of achieving zero environmental impact, NTT is conducting R&D to create the innovations needed to achieve this goal, and carrying out its business activities in a manner that reduces its effects on the environment. Safe and permanent fusion energy is one of the most promising technologies in this important endeavor. We believe that NTT’s groundbreaking R&D activities, including IOWN, and our ability to construct global infrastructure can make a valuable contribution to the ITER Organization, a leading research entity in this area. Under this agreement, we will work closely with the ITER Organization to demonstrate the feasibility of fusion power at an industrial scale for the first time in human history.”
-Jun Sawada
, President & CEO, NTT
“We, with the seven ITER Members, believe that fusion power can become a clean and safe vital contributor to the global energy mix for our civilization starting in this century for numerous millennium, and the progress of the ITER Project is essential for that path. I am pleased to have global ICT companies like NTT as one of our long-term non-commercial collaboration partners, with the solid capacity to develop advanced global ICT technologies as well as the capability to envision innovative future technologies strategies such as the IOWN concept that fusion will definitively need.”
-Bernard Bigot
, Director-General, the ITER Organization
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005951/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
